Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Transitional care strategies focused on enhancing the accuracy and comprehensiveness of medication information transfer will lead to improved health outcomes among hospitalized patients with chronic kidney disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medication Reconciliation in Hospitalized CKD Patients : a Quasi-Experimental Study

NCT06819527

Chronic Kidney Disease(CKD)

COMPLETED NA

Mobile Health Technology for Chronic Kidney Disease Patients: Medication Management

NCT02905474

Renal Insufficiency, Chronic Hypertension Medication Reconciliation +1 more

COMPLETED NA

Multi-Center Medication Reconciliation Quality Improvement Study

NCT01337063

Adverse Drug Events Medication Administered in Error

COMPLETED NA

Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge

NCT01179867

Medication Reconciliation Adverse Drug Events

COMPLETED NA

Patient-driven Management of BP in CKD

NCT05546099

Chronic Kidney Disease

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with CKD and ESRD have more co-morbidities, are hospitalized more often and for longer lengths of stay, and incur greater healthcare costs than patients with other chronic conditions. Enhanced hospital to home transitional care interventions have been shown to improve medication information transfer, reduce hospital readmissions, and slow the progression of declining health in the general population of hospitalized patients. What is not known is the impact enhanced transitional care can have for a very high-risk population, such as those with CKD and ESRD. Interventions that prevent or slow CKD progression, i.e. blood pressure control and intensive glycemic control in patients with diabetes, are all highly dependent on meticulous medication management.

For hospitalized patients with CKD or ESRD who are transitioning to home, accurate and comprehensive information transfer is essential to optimal medication management. CKD and ESRD patients are in critical need of improved transitional care that includes accurate and comprehensive medication information transfer. The main objective of this application is to pilot-test the effectiveness of a medication information transfer intervention to improve clinically-relevant outcomes. To this end, the following Specific Aims will be achieved: 1. Evaluate the impact of transitional care interventions on acute care utilization following hospital discharge among patients with CKD or ESRD. 2. Evaluate the impact of transitional care strategies on management of CKD or ESRD management and complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease End-Stage Renal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control

usual care for hospital discharge:

1. CKD group
2. ESRD group

Group Type ACTIVE_COMPARATOR

Usual care for hospital discharge

Intervention Type OTHER

Patients will receive medication information according to standard practice for discharge of hospitalized patients.

intervention

pharmacist administered medication information transfer intervention

1. CKD group
2. ESRD group

Group Type ACTIVE_COMPARATOR

Medication Information Transfer Intervention

Intervention Type OTHER

A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medication Information Transfer Intervention

A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.

Intervention Type OTHER

Usual care for hospital discharge

Patients will receive medication information according to standard practice for discharge of hospitalized patients.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Hospitalized patients
2. \> 21 years of age
3. Diagnosis of CKD stages 3-5, not treated by dialysis

1. Hospitalized patients
2. \> 21 years of age
3. Patients treated with hemodialysis or peritoneal dialysis